[go: up one dir, main page]

TN2010000016A1 - Novel antibodies inhibiting c-met dimerization, and uses thereof - Google Patents

Novel antibodies inhibiting c-met dimerization, and uses thereof

Info

Publication number
TN2010000016A1
TN2010000016A1 TNP2010000016A TN2010000016A TN2010000016A1 TN 2010000016 A1 TN2010000016 A1 TN 2010000016A1 TN P2010000016 A TNP2010000016 A TN P2010000016A TN 2010000016 A TN2010000016 A TN 2010000016A TN 2010000016 A1 TN2010000016 A1 TN 2010000016A1
Authority
TN
Tunisia
Prior art keywords
met
novel antibodies
met dimerization
antibodies inhibiting
antibodies
Prior art date
Application number
TNP2010000016A
Other languages
English (en)
Inventor
Liliane Goetsch
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38871713&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2010000016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of TN2010000016A1 publication Critical patent/TN2010000016A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G01N33/5759—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
TNP2010000016A 2007-07-12 2010-01-08 Novel antibodies inhibiting c-met dimerization, and uses thereof TN2010000016A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301231A EP2014681A1 (fr) 2007-07-12 2007-07-12 Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes
PCT/EP2008/059026 WO2009007427A2 (fr) 2007-07-12 2008-07-10 Nouveaux anticorps inhibant la dimérisation de c-met et utilisations de ceux-ci

Publications (1)

Publication Number Publication Date
TN2010000016A1 true TN2010000016A1 (en) 2011-09-26

Family

ID=38871713

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000016A TN2010000016A1 (en) 2007-07-12 2010-01-08 Novel antibodies inhibiting c-met dimerization, and uses thereof

Country Status (35)

Country Link
US (6) US8329173B2 (fr)
EP (6) EP2014681A1 (fr)
JP (4) JP5562844B2 (fr)
KR (4) KR101719084B1 (fr)
CN (4) CN103509112B (fr)
AR (4) AR067517A1 (fr)
AU (1) AU2008274171B2 (fr)
BR (1) BRPI0815564B8 (fr)
CA (4) CA2694418C (fr)
CL (1) CL2008002015A1 (fr)
CO (1) CO6170364A2 (fr)
CY (1) CY1116608T1 (fr)
DK (1) DK2188312T3 (fr)
ES (5) ES2542059T3 (fr)
HR (1) HRP20150887T1 (fr)
HU (1) HUE026026T2 (fr)
IL (5) IL203114A (fr)
MA (1) MA31977B1 (fr)
ME (1) ME02341B (fr)
MX (3) MX345391B (fr)
MY (1) MY158756A (fr)
NZ (4) NZ599959A (fr)
PA (1) PA8789201A1 (fr)
PH (3) PH12018502039A1 (fr)
PL (1) PL2188312T3 (fr)
PT (1) PT2188312E (fr)
RS (1) RS54197B1 (fr)
RU (1) RU2552161C2 (fr)
SA (1) SA08290423B1 (fr)
SG (1) SG183015A1 (fr)
SI (1) SI2188312T1 (fr)
TN (1) TN2010000016A1 (fr)
TW (4) TWI602829B (fr)
WO (1) WO2009007427A2 (fr)
ZA (1) ZA201000966B (fr)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143441A1 (fr) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combinaison d'antagoniste c-MET et composé d'aminihétéroaryl pour le traitement du cancer
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US9469691B2 (en) * 2008-12-02 2016-10-18 Pierre Fabre Medicament Anti-cMET antibody
AR074439A1 (es) * 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
US20140112911A9 (en) * 2008-12-02 2014-04-24 Liliane Goetsch Novel anti-cmet antibody
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
RU2011144312A (ru) 2009-04-07 2013-05-20 Роше Гликарт Аг БИСПЕЦИФИЧЕСКИЕ АНТИ-ErbB-3/АНТИ-С-МЕТ АНТИТЕЛА
CA2757426A1 (fr) 2009-04-07 2010-10-14 Roche Glycart Ag Anticorps anti-erbb-2/anti-c-met bispecifiques
EP2287197A1 (fr) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anticorps anti-cMET et son utilisation pour la détection et le diagnostic du cancer
KR101671378B1 (ko) 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
KR101748707B1 (ko) 2009-11-27 2017-06-20 삼성전자주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
PT3904391T (pt) * 2010-03-10 2024-10-14 Genmab As Anticorpos monoclonais contra c-met
JP2013534515A (ja) * 2010-06-01 2013-09-05 モナシュ ユニバーシティ プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体
EP2402370A1 (fr) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Nouvel anticorps pour le diagnostic et/ou le pronostic du cancer
JP2013532627A (ja) 2010-07-01 2013-08-19 武田薬品工業株式会社 ｃＭＥＴ阻害剤とＨＧＦおよび／またはｃＭＥＴに対する抗体との組み合わせ
CA2808236A1 (fr) 2010-08-31 2012-03-08 Genentech, Inc. Biomarqueurs et procedes de traitement
RU2013114783A (ru) * 2010-09-03 2014-10-10 Академиа Синика Anti-с-мет антитела и способы их применения
WO2012042026A1 (fr) 2010-09-30 2012-04-05 Ablynx Nv Matières biologiques associées à c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CA2816919A1 (fr) 2010-11-03 2012-05-10 Anna Hultberg Combinaisons d'anticorps c-met
EA201390611A1 (ru) 2010-11-24 2014-01-30 Глаксо Груп Лимитед Мультиспецифические антигенсвязывающие белки, направленные на hgf
KR101444837B1 (ko) 2011-06-03 2014-09-30 한국생명공학연구원 ＨＧＦ 활성을 가지는 ｃ-Ｍｅｔ에 대한 인간항체 및 이의 용도
PH12022550310A1 (en) 2011-06-23 2023-01-23 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN103619878B (zh) * 2011-06-23 2016-10-26 埃博灵克斯股份有限公司 结合血清白蛋白的蛋白
BR112013030472A2 (pt) * 2011-06-30 2019-09-24 Genentech Inc formulação farmacêutica, artigo de fabricação e método
HK1199883A1 (en) 2011-08-26 2015-07-24 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
MX2014002990A (es) 2011-09-19 2014-05-21 Genentech Inc Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf.
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
EP2747783B1 (fr) 2011-09-30 2017-06-14 Ablynx N.V. Substances biologiques liées à c-met
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
KR20130037153A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 항 ｃ-Ｍｅｔ 항체 및 그의 용도
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
KR101865223B1 (ko) * 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
WO2013064700A2 (fr) 2011-11-03 2013-05-10 Argen-X B.V. Polypeptides chimériques et leurs procédés d'utilisation
US20130129718A1 (en) 2011-11-21 2013-05-23 Genentech, Inc. Purification of anti-c-met antibodies
US20150147274A1 (en) 2011-12-02 2015-05-28 Cancer Research Technology Limited Antibodies against hgf - receptor and uses
KR101910601B1 (ko) 2011-12-22 2018-10-23 삼성전자주식회사 면역원성이 제거된 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
US9376485B2 (en) 2012-02-29 2016-06-28 The Brigham And Women's Hospital, Inc. Neutralizing antibody for epstein barr virus-associated disease
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
CA2877573A1 (fr) 2012-06-21 2013-12-27 Sorrento Therapeutics, Inc. Proteines de liaison a un antigene qui se lient a c-met
KR101938699B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｌｒｉｇ１의 항 ｃ―ｍｅｔ 항체 적용 대상 환자 선별을 위한 용도
KR101938698B1 (ko) 2012-07-23 2019-01-16 삼성전자주식회사 Ｃｂｌ의 항 ｃ－ｍｅｔ 항체 적용 대상 환자 선별을 위한 바이오마커로서의 용도
AU2013302441B2 (en) * 2012-08-17 2018-05-10 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
EP2894472A4 (fr) * 2012-09-05 2016-03-30 Jsr Corp Procédé de criblage de matière agissant sur une maintenance épithéliale de cellules
WO2014057074A1 (fr) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
WO2014067642A1 (fr) 2012-11-05 2014-05-08 Mab Discovery Gmbh Procédé de fabrication d'anticorps plurispécifiques
EP2727941A1 (fr) 2012-11-05 2014-05-07 MAB Discovery GmbH Procédé pour la production d'anticorps multispécifiques
WO2014074907A1 (fr) * 2012-11-09 2014-05-15 Indi Molecular, Inc. Agents de capture spécifiques de c-met, compositions et procédés d'utilisation et de fabrication
KR101911048B1 (ko) 2013-01-29 2018-10-24 삼성전자주식회사 ｐ５３ 활성화제 및 ｃ－Ｍｅｔ 억제제를 포함하는 병용 투여용 약학 조성물
HK1211235A1 (en) 2013-02-22 2016-05-20 霍夫曼-拉罗奇有限公司 Methods of treating cancer and preventing drug resistance
EA201591652A1 (ru) 2013-03-06 2016-02-29 Мерримак Фармасьютикалз, Инк. ТАНДЕМНЫЕ БИСПЕЦИФИЧЕСКИЕ Fc-АНТИТЕЛА ПРОТИВ c-MET
JP6444902B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びその結合体
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
KR102139607B1 (ko) * 2013-04-01 2020-07-30 삼성전자주식회사 항 c-Met 항체 및 FGFR 저해제를 포함하는 병용 투여용 약학 조성물
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
WO2015031626A1 (fr) 2013-08-28 2015-03-05 Abbvie Inc. Dosage de cmet soluble
WO2015031614A1 (fr) * 2013-08-28 2015-03-05 Abbvie Inc. Dosage de la cmet soluble
WO2015051159A1 (fr) * 2013-10-02 2015-04-09 The Rockefeller University Anticorps de protofibrilles amyloïdes et leurs procédés d'utilisation
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
EP3122900A1 (fr) 2014-03-24 2017-02-01 F. Hoffmann-La Roche AG Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
CN106661622B (zh) 2014-05-23 2020-08-21 豪夫迈·罗氏有限公司 Mit生物标志物和使用它们的方法
JP6531166B2 (ja) 2014-09-10 2019-06-12 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
WO2016053610A1 (fr) * 2014-10-03 2016-04-07 Academia Sinica Anticorps contre les formes pathologiques de tdp-43 et utilisations de ces derniers
EP3200825A4 (fr) 2014-10-03 2018-03-21 Academia Sinica Anticorps contre les formes pathologiques de tdp-43 et utilisations de ces derniers
EP3221468B1 (fr) * 2014-11-20 2020-03-25 Stichting Katholieke Universiteit Nouveau mutant intracellulaire à activation automatique de met
WO2016091891A1 (fr) 2014-12-09 2016-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps monoclonaux humains contre axl
PL3233910T3 (pl) 2014-12-19 2020-06-01 Ablynx N.V. Dimery nanociał połączone cysteiną
WO2016135041A1 (fr) 2015-02-26 2016-09-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Protéines de fusion et anticorps les contenant pour favoriser l'apoptose
CN113150147A (zh) * 2015-03-16 2021-07-23 塞尔德克斯医疗公司 抗-met抗体及其使用方法
EP3277316B1 (fr) 2015-04-02 2025-03-05 Ablynx N.V. Polypeptides cxcr4-cd-4 bispécifiques à activité anti-vih puissante
TW201709932A (zh) 2015-06-12 2017-03-16 西雅圖遺傳學公司 Ｃｄ１２３抗體及其共軛物
US20190194345A1 (en) * 2015-10-05 2019-06-27 University Of Virginia Patent Foundation Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer
EP3909984A1 (fr) 2015-11-03 2021-11-17 Merck Patent GmbH Anticorps c-met maturés par affinité
EP3436480A4 (fr) * 2016-03-30 2019-11-27 Musc Foundation for Research Development Méthodes pour le traitement et le diagnostic du cancer par le ciblage d'une protéine à prédominance de répétitions de glycoprotéine a (garp) et la mise en uvre d'une immunothérapie efficace seule ou en association
HUE053332T2 (hu) 2016-05-17 2021-06-28 Abbvie Biotherapeutics Inc Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra
JP7120989B2 (ja) * 2016-07-06 2022-08-17 セルジーン コーポレイション 低免疫原性を有する抗体及びその使用
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
WO2018129029A1 (fr) 2017-01-04 2018-07-12 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
US11525004B2 (en) 2017-07-20 2022-12-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Recombinant CD123-binding antibodies
WO2019117691A1 (fr) * 2017-12-15 2019-06-20 경북대학교 산학협력단 Peptides se liant à cd44v6 et utilisation correspondante
KR102194025B1 (ko) 2017-12-15 2020-12-22 경북대학교 산학협력단 CD44v6에 결합하는 펩타이드 및 이의 용도
TWI842701B (zh) * 2018-03-24 2024-05-21 美商再生元醫藥公司 用於產生抗肽-mhc複合物之治療性抗體的經基因修飾的非人類動物、其製法與用途
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
WO2020014306A1 (fr) 2018-07-10 2020-01-16 Immunogen, Inc. Anticorps anti-met, immunoconjugués et utilisations de ceux-ci
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
US12384811B2 (en) 2019-04-05 2025-08-12 Academia Sinica Sialidase-resistant saccharide and method of making and using the same
AU2020349462A1 (en) 2019-09-16 2022-03-03 Regeneron Pharmaceuticals, Inc. Radiolabeled MET binding proteins for immuno-PET imaging
MX2022014013A (es) 2020-05-08 2023-01-30 Academia Sinica Vacunas quimericas contra la influenza.
WO2022079211A1 (fr) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugués
WO2022126416A1 (fr) * 2020-12-16 2022-06-23 武汉友芝友生物制药股份有限公司 Anticorps anti-bcma, son procédé de préparation et son application
CN112679614B (zh) * 2021-01-15 2022-08-16 广东安普泽生物医药股份有限公司 用于特异性结合rankl靶向治疗药物的抗体及其用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
CN112946279A (zh) * 2021-03-17 2021-06-11 扬州大学 一种基于油水界面自组装的三明治sers免疫传感器检测宫颈癌患者血清生物标志物方法
EP4319811A1 (fr) 2021-04-06 2024-02-14 Abbvie Biotherapeutics Inc. Méthodes de traitement du cancer du poumon non à l'aide de telisotuzumab vedotin
KR20250106328A (ko) 2021-04-12 2025-07-09 아카데미아 시니카 개선된 코로나바이러스 백신
TWI895608B (zh) 2021-04-29 2025-09-01 愛爾蘭商艾伯維製造管理無限公司 抗c-Met抗體藥物結合物
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
EP4426727A2 (fr) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
US20230279080A1 (en) * 2021-12-27 2023-09-07 Academia Sinica Antibody specific to spike protein of sars-cov-2 and uses thereof
TW202434637A (zh) * 2022-12-20 2024-09-01 美商翰森生物有限責任公司 抗體、抗原結合片段及其醫藥用途
AU2024252371B2 (en) 2023-04-08 2026-02-12 Rock Biomedical Inc. Methods and compositions for dendritic cell targeting nano-delivery
AU2024255035B2 (en) 2023-04-08 2025-08-07 Rock Biomedical Inc. Methods and compositions for targeted delivery by polymersomes
WO2024238734A2 (fr) 2023-05-17 2024-11-21 Rock Biomedical Inc. Cellules déficientes en mgat1 et leurs utilisations
WO2025025434A1 (fr) * 2023-08-02 2025-02-06 百泰生物药业有限公司 Anticorps bispécifique egfr/c-met et son utilisation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2840250C2 (de) 1978-09-15 1983-01-20 Siemens AG, 1000 Berlin und 8000 München Schaltungsanordnung für eine leitungsgespeiste Lautfernsprechstation
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
CN100387621C (zh) * 1997-04-14 2008-05-14 麦可麦脱股份公司 抗人抗原受体的新的生产方法及其用途
US7563874B2 (en) * 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
CN1646161A (zh) * 2002-02-21 2005-07-27 杜克大学 自身免疫疾病的药剂和治疗方法
EP1592713A2 (fr) * 2003-02-13 2005-11-09 Pharmacia Corporation Anticorps contre c-met dans le traitement de cancers
JP5416338B2 (ja) * 2003-05-09 2014-02-12 デューク ユニバーシティ Ｃｄ２０特異的抗体およびその使用方法
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
EP1692178A1 (fr) * 2003-12-11 2006-08-23 Genentech, Inc. Methodes et compositions pour inhiber une dimerisation et une activation de c-met
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
US20060094059A1 (en) 2004-09-22 2006-05-04 Odyssey Thera, Inc. Methods for identifying new drug leads and new therapeutic uses for known drugs
CA2597265C (fr) * 2005-02-10 2015-03-24 Baylor Research Institute Anticorps monoclonaux anti-interferon alpha et procedes d'utilisation
CA2606102C (fr) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine "charniere"
JP5142998B2 (ja) 2005-07-18 2013-02-13 アムジエン・インコーポレーテツド ヒト抗ｂ７ｒｐ１中和抗体
EP1913027B1 (fr) 2005-07-28 2015-03-04 Novartis AG Anticorps monoclonal specifique de m-csf et ses utilisations
KR101429297B1 (ko) 2006-02-06 2014-08-12 메테레시스 트랜스레이셔날 리서치 에스.에이. 종양 치료를 위한 항-Ｍｅｔ 단클론 항체, 이의 단편과벡터 및 상응하는 산물
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
EP2143441A1 (fr) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combinaison d'antagoniste c-MET et composé d'aminihétéroaryl pour le traitement du cancer
AR074439A1 (es) 2008-12-02 2011-01-19 Pf Medicament Anticuerpo anti-cmet (receptor c-met)
WO2010064089A1 (fr) 2008-12-02 2010-06-10 Pierre Fabre Medicament Nouvel anticorps anti-cmet

Also Published As

Publication number Publication date
US9107907B2 (en) 2015-08-18
US8329173B2 (en) 2012-12-11
CL2008002015A1 (es) 2008-11-21
IL223108B (en) 2019-06-30
DK2188312T3 (en) 2015-08-03
AR109535A2 (es) 2018-12-19
TWI592427B (zh) 2017-07-21
EP2415785B1 (fr) 2018-04-25
CN101981054A (zh) 2011-02-23
CN103509113A (zh) 2014-01-15
AR109659A2 (es) 2019-01-09
CA2888691A1 (fr) 2009-01-15
CN101981054B (zh) 2015-04-15
NZ613716A (en) 2015-01-30
IL223105B (en) 2020-02-27
TW201437231A (zh) 2014-10-01
HUE026026T2 (en) 2016-05-30
TW201605892A (zh) 2016-02-16
CA2694418C (fr) 2018-03-27
JP5889923B2 (ja) 2016-03-22
EP2535356B1 (fr) 2018-06-13
ES2693542T3 (es) 2018-12-12
JP2010532982A (ja) 2010-10-21
SG183015A1 (en) 2012-08-30
CO6170364A2 (es) 2010-06-18
KR101625234B1 (ko) 2016-05-30
IL223109A0 (en) 2012-12-31
ZA201000966B (en) 2011-02-23
JP5889924B2 (ja) 2016-03-22
ES2678495T3 (es) 2018-08-13
CA2888691C (fr) 2023-01-03
TWI602830B (zh) 2017-10-21
PT2188312E (pt) 2015-10-05
CN103509113B (zh) 2015-10-21
CA2694418A1 (fr) 2009-01-15
EP2188312A2 (fr) 2010-05-26
KR101719084B1 (ko) 2017-03-22
EP2535357B1 (fr) 2018-08-08
US8871910B2 (en) 2014-10-28
CA2981821C (fr) 2020-07-28
EP2535357A1 (fr) 2012-12-19
US8889832B2 (en) 2014-11-18
PA8789201A1 (es) 2009-08-26
JP5562844B2 (ja) 2014-07-30
CN103183739B (zh) 2016-08-17
AR067517A1 (es) 2009-10-14
EP2415784A1 (fr) 2012-02-08
TW201605891A (zh) 2016-02-16
BRPI0815564B8 (pt) 2021-05-25
US8871909B2 (en) 2014-10-28
JP2014113155A (ja) 2014-06-26
US20150252114A1 (en) 2015-09-10
KR20150070451A (ko) 2015-06-24
RS54197B1 (sr) 2015-12-31
KR20160019975A (ko) 2016-02-22
NZ599959A (en) 2013-11-29
NZ583041A (en) 2012-06-29
HK1193619A1 (zh) 2014-09-26
US20130273060A1 (en) 2013-10-17
PH12018502039A1 (en) 2019-08-19
CA2982484C (fr) 2021-06-01
US20130272957A1 (en) 2013-10-17
ES2686693T3 (es) 2018-10-19
EP2014681A1 (fr) 2009-01-14
MX341012B (es) 2016-08-03
HK1193620A1 (zh) 2014-09-26
IL223108A0 (en) 2012-12-31
KR20160019974A (ko) 2016-02-22
SA08290423B1 (ar) 2013-12-23
CN103183739A (zh) 2013-07-03
TW200911828A (en) 2009-03-16
JP5889925B2 (ja) 2016-03-22
US20100115639A1 (en) 2010-05-06
AU2008274171B2 (en) 2014-02-27
CA2982484A1 (fr) 2009-01-15
BRPI0815564B1 (pt) 2020-01-21
CA2981821A1 (fr) 2009-01-15
MX345391B (es) 2017-01-27
IL223109B (en) 2019-06-30
BRPI0815564A2 (pt) 2015-02-18
WO2009007427A2 (fr) 2009-01-15
ES2542059T3 (es) 2015-07-30
ES2686335T3 (es) 2018-10-17
MX353449B (es) 2018-01-08
AR109660A2 (es) 2019-01-09
RU2552161C2 (ru) 2015-06-10
PH12018502038A1 (en) 2019-08-19
US20130280257A1 (en) 2013-10-24
KR101701686B1 (ko) 2017-02-01
NZ599958A (en) 2013-11-29
EP2188312B1 (fr) 2015-05-27
IL223106B (en) 2020-06-30
PH12018502040A1 (en) 2019-08-19
ME02341B (fr) 2015-12-31
KR20100044212A (ko) 2010-04-29
RU2010104633A (ru) 2011-08-20
EP2415784B1 (fr) 2018-06-13
PL2188312T3 (pl) 2016-01-29
EP2535356A1 (fr) 2012-12-19
CN103509112B (zh) 2015-10-21
IL223105A0 (en) 2012-12-31
IL223106A0 (en) 2012-12-31
US20140010818A1 (en) 2014-01-09
HRP20150887T1 (hr) 2015-09-25
WO2009007427A3 (fr) 2009-04-09
EP2415785A1 (fr) 2012-02-08
JP2014113153A (ja) 2014-06-26
SI2188312T1 (sl) 2015-09-30
CY1116608T1 (el) 2017-03-15
CN103509112A (zh) 2014-01-15
IL203114A (en) 2015-03-31
HK1149024A1 (en) 2011-09-23
TWI602829B (zh) 2017-10-21
AU2008274171A1 (en) 2009-01-15
TWI549965B (zh) 2016-09-21
MY158756A (en) 2016-11-15
MA31977B1 (fr) 2011-01-03
KR101701685B1 (ko) 2017-02-01
JP2014113154A (ja) 2014-06-26

Similar Documents

Publication Publication Date Title
PH12018502039A1 (en) Novel antibodies inhibiting c-met dimerization, and uses thereof
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MY148496A (en) Dpp iv inhibitor formulations
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
NZ604056A (en) Novel anti-cmet antibody
TN2010000140A1 (en) Compositions and methods for use antibodies against sclerostin
WO2008046509A8 (fr) Protéine ltbp2 utilisée en tant que biomarqueur, cible thérapeutique et diagnostique
SG169988A1 (en) Rnai inhibition of alpha-enac expression
WO2009142738A3 (fr) Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
WO2009089537A3 (fr) Composés anticancéreux
MY160800A (en) 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
WO2008112290A3 (fr) Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l'ovaire
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
WO2007059154A3 (fr) Traitement de cancers a resistance acquise a des inhibiteurs de kit
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
MX2009009831A (es) Nitrilos aromatizantes.
EP2124554A4 (fr) Compositions et procédés pour le traitement du cancer
WO2008053270A3 (fr) Utilisation d'un antagoniste du récepteur egfr pour le traitement de la glomérulonéphrite
WO2009126335A3 (fr) Composés inhibiteurs d’ant2 et procédés d’utilisation de ceux-ci
WO2010129890A3 (fr) Composés et procédés pour inhiber l'agrégation plaquettaire
WO2009151495A3 (fr) Composés oxazoles, compositions et procédés d'utilisation
TN2011000150A1 (en) Anti cxcr4 antibodies and their use for the treatment of cancer
WO2007095293A3 (fr) PLASMA de patients atteints de vitiligo pour le traitement d'un melanome